NICE to look at obesity, cancer and arthritis
Viewing Medicine
Obesity treatments will be assessed |
New drugs for the treatment of obesity, cancer, rheumatoid arthritis and Crohn's disease are being looked at by the National Institute for Health and Clinical Excellence for future use in the NHS in England and Wales, it was announced last week.
New clinical guidelines for the treatment and management of acute diarrhoea
and vomiting in children and another, devoted to the treatment of adults
with rheumatoid arthritis, are also being developed as part of the institute’s
13th work programme, according to details revealed by the Department
of Health.
New drugs which are being appraised for the NHS on the grounds of their
cost and clinical effectiveness are: adalimumab for patients with moderate
to severe Crohn’s disease; certolizumab pegol for the treatment
of rheumatoid arthritis; lapatinib plus capecitabine for advanced, metastatic
or recurrent breast cancer; and bevacizumab for the treatment of lung
cancer.
The suitability of rimonabant in the treatment of obesity in conjunction
with exercise and diet is also being appraised.
The latest programme also involves NICE looking at the clinical and cost
effectiveness of infliximab for patients with ulcerative colitis, and
new rapid clinical guidelines on the care of acutely ill patients in
hospital are also being developed. NICE is also going to focus on the
most effective way to store and preserve donated kidneys.
|
The
Pharmaceutical Journal
Acrobat
Reader